All In Biotech

Drug Trial Radar · NCT07141199

A Study to Evaluate Adverse Events, How the Drug is Tolerated, and How the Drug Moves Through the Body of Intravenous Infusions of ABBV-8736 in Adult Healthy Volunteers

A Phase 1, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of ABBV-8736 After Multiple Ascending Doses in Healthy Adult Subjects

Last checked: Nov 19, 2026Latest source record: Apr 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

24

Actual

Start

Sep 2, 2025

Primary completion

Mar 23, 2026

Study completion Mar 23, 2026

Sponsor

Lead sponsor
AbbVieAbbVie (ABBV)
Sponsor type
Industry
First posted
Aug 26, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, care provider)
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The objective of this study is to assess the safety, tolerability, pharmacokinetics, and immunogenicity following multiple intravenous (IV) ascending doses of ABBV-8736 in healthy adult participants.

Conditions

  • Healthy Volunteer

Interventions

  • ABBV-8736Drug

    Intravenous (IV) Infusion

  • PlaceboDrug

    IV Infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with Adverse Events (AEs)Time frame: Up to Approximately 113 Days
  2. Maximum Observed Concentration (Cmax) of ABBV-8736Time frame: Up to Approximately 113 Days
  3. Time to Cmax (Tmax) of ABBV-8736Time frame: Up to Approximately 113 Days
  4. Area under the plasma concentration-time curve from time 0 until the last measurable concentration (AUCtau) of ABBV-8736Time frame: Up to Approximately 113 Days
  5. Observed plasma concentration at the end of a dosing interval (Ctrough) of ABBV-8736Time frame: Up to Approximately 113 Days
  6. Apparent Terminal Phase Elimination Rate Constant (β) of ABBV-8736Time frame: Up to Approximately 113 Days
  7. Terminal Phase Elimination Half-Life (t1/2) of ABBV-8736Time frame: Up to Approximately 113 Days
  8. Clearance (CL) for Intravenous (IV) DosingTime frame: Up to Approximately 113 Days
  9. Immunogenicity of ABBV-8736 as Determined by Anti-Drug Antibodies (ADAs)Time frame: Up to Approximately 113 Days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Acpru /Id# 277377

    Grayslake, Illinois

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.